KMDA Kamada

Kamada Provides Update on 2021 GLASSIA® Supply to Takeda

Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
EN
07/10/2020

Underlying

KMDAKamada

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kamada

 PRESS RELEASE
Free
KMDA KAMADA

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Resu...

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company's Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Generated $17.9 Million of Cash f...

November 10, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada Announces First Patient Enrolled into an Investigator-Initiated...

Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation Post Marketing Study to Evaluate the Role of CYTOGAM in the Reduction of Risk of Late CMV Disease Following the Conclusion of Standardly Prescribed Antiviral Treatment in High-Risk Kidney Transplant Recipients REHOVOT, Israel, and HOBOKEN, N.J. , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and...

November 4, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2...

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025 Company to Host Conference Call at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of...

November 3, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada to Present at the Stifel 2025 Healthcare Conference

Kamada to Present at the Stifel 2025 Healthcare Conference REHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate in the Stifel 2025 Healthcare Conference, to be held to be held at the Lotte New York Palace Hotel, New-York, NY on November 11–13, 2025. Mr. London is scheduled to present at 9:20...

October 29, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada to Participate in Upcoming September Investor Conferences

Kamada to Participate in Upcoming September Investor Conferences REHOVOT, Israel, and HOBOKEN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate in the 2025 Wells Fargo Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. Mr. London is scheduled to present at the 2025 Wells Fargo...

September 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch